KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Shares Outstanding (Diluted Average) (2018 - 2025)

Historic Shares Outstanding (Diluted Average) for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q3 2025 value amounting to $324.8 million.

  • Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) rose 487.88% to $324.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $324.8 million, marking a year-over-year increase of 487.88%. This contributed to the annual value of $309.0 million for FY2024, which is 7542.01% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Shares Outstanding (Diluted Average) of $324.8 million as of Q3 2025, which was up 487.88% from $323.2 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' 5-year Shares Outstanding (Diluted Average) high stood at $324.8 million for Q3 2025, and its period low was $149.9 million during Q1 2022.
  • Moreover, its 5-year median value for Shares Outstanding (Diluted Average) was $157.3 million (2023), whereas its average is $217.6 million.
  • In the last 5 years, Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) tumbled by 87.82% in 2022 and then skyrocketed by 10592.88% in 2024.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $151.7 million in 2021, then fell by 0.47% to $150.9 million in 2022, then increased by 16.69% to $176.1 million in 2023, then skyrocketed by 75.42% to $309.0 million in 2024, then increased by 5.11% to $324.8 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $324.8 million in Q3 2025, compared to $323.2 million in Q2 2025 and $324.0 million in Q1 2025.